"Rise of Targeted Immunotherapies and Vaccine Development"
- A key trend in the EBV drug market is the emergence of immune-based strategies targeting latent viral reservoirs and associated cancers. Novel immunotherapies and vaccine candidates are reshaping disease management paradigms
- For instance, In January 2025, a Phase I clinical trial began in the U.S. to test a nanoparticle-based EBV vaccine aimed at preventing infectious mononucleosis and reducing the risk of lymphoma development.
- This innovation signals a pivotal shift in EBV management, from symptomatic treatment to preemptive and precision-based interventions, with the potential to drastically reduce EBV-associated disease burdens
